EFFICACY OF SGLT-2 INHIBITORS IN THE TREATMENT OF TYPE 2 DIABETES: SINGLE CENTRE EXPERIENCE
Objective: Sodium-glucose transporter-2 (SGLT-2) inhibitors lower blood glucose levels by reducing renal glucose reabsorption without affecting insulin secretion. The aim of our study was to evaluate the effect of SGLT-2 inhibitor treatment on glycemic control and the possible superiority of the dru...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Istanbul University Press
2025-01-01
|
| Series: | İstanbul Tıp Fakültesi Dergisi |
| Subjects: | |
| Online Access: | https://cdn.istanbul.edu.tr/file/JTA6CLJ8T5/A4D4179A8B4040629597C48450358B95 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850032409258491904 |
|---|---|
| author | Ramazan Çakmak Golpouneh Alizad Oghyanous Özlem Soyluk Selçukbiricik Kubilay Karşıdağ |
| author_facet | Ramazan Çakmak Golpouneh Alizad Oghyanous Özlem Soyluk Selçukbiricik Kubilay Karşıdağ |
| author_sort | Ramazan Çakmak |
| collection | DOAJ |
| description | Objective: Sodium-glucose transporter-2 (SGLT-2) inhibitors lower blood glucose levels by reducing renal glucose reabsorption without affecting insulin secretion. The aim of our study was to evaluate the effect of SGLT-2 inhibitor treatment on glycemic control and the possible superiority of the drugs by comparing clinical parameters and laboratory findings in Type 2 diabetes mellitus (T2DM) patients. Material and Methods: Two hundred and nineteen T2DM patients who received SGLT-2 inhibitor therapy [empagliflozin (EMPA) (n=146) or dapagliflozin (DAPA) (n=73)/10 mg] were enrolled retrospectively. The patients’ demographic characteristics, detailed medical history, comorbidities, physical examination findings, complications, weight and systolic-diastolic blood pressure follow-up, laboratory findings (at baseline, 3rd, and 12th month), and overall follow-up outcomes were evaluated. Result: The mean values of HbA1c and fasting blood glucose (FBG) decreased significantly compared with the baseline values after the treatment. The mean body weight and uric acid values were significantly reduced in the 3rd month of the treatment. Similarly, the values of the liver function tests decreased substantially after treatment. Conclusion: The beneficial effects of SGLT-2 inhibitors on glycemic control and liver functions in patients with T2DM have been demonstrated. In addition, there was no major difference in terms of clinical parameters, laboratory findings, and drug safety in patients between EMPA and DAPA. |
| format | Article |
| id | doaj-art-34b198bd5e0147f9a44549f1c62bdfd1 |
| institution | DOAJ |
| issn | 1305-6441 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Istanbul University Press |
| record_format | Article |
| series | İstanbul Tıp Fakültesi Dergisi |
| spelling | doaj-art-34b198bd5e0147f9a44549f1c62bdfd12025-08-20T02:58:39ZengIstanbul University Pressİstanbul Tıp Fakültesi Dergisi1305-64412025-01-01881455210.26650/IUITFD.1508775123456EFFICACY OF SGLT-2 INHIBITORS IN THE TREATMENT OF TYPE 2 DIABETES: SINGLE CENTRE EXPERIENCERamazan Çakmak0Golpouneh Alizad Oghyanous1https://orcid.org/0000-0002-5047-4007Özlem Soyluk Selçukbiricik2https://orcid.org/0000-0003-0732-4764Kubilay Karşıdağ3https://orcid.org/0000-0002-9332-1262İstanbul Üniversitesi, İstanbul, Türkiyeİstanbul Üniversitesi, İstanbul, Türkiyeİstanbul Üniversitesi, İstanbul, Türkiyeİstanbul Üniversitesi, İstanbul, TürkiyeObjective: Sodium-glucose transporter-2 (SGLT-2) inhibitors lower blood glucose levels by reducing renal glucose reabsorption without affecting insulin secretion. The aim of our study was to evaluate the effect of SGLT-2 inhibitor treatment on glycemic control and the possible superiority of the drugs by comparing clinical parameters and laboratory findings in Type 2 diabetes mellitus (T2DM) patients. Material and Methods: Two hundred and nineteen T2DM patients who received SGLT-2 inhibitor therapy [empagliflozin (EMPA) (n=146) or dapagliflozin (DAPA) (n=73)/10 mg] were enrolled retrospectively. The patients’ demographic characteristics, detailed medical history, comorbidities, physical examination findings, complications, weight and systolic-diastolic blood pressure follow-up, laboratory findings (at baseline, 3rd, and 12th month), and overall follow-up outcomes were evaluated. Result: The mean values of HbA1c and fasting blood glucose (FBG) decreased significantly compared with the baseline values after the treatment. The mean body weight and uric acid values were significantly reduced in the 3rd month of the treatment. Similarly, the values of the liver function tests decreased substantially after treatment. Conclusion: The beneficial effects of SGLT-2 inhibitors on glycemic control and liver functions in patients with T2DM have been demonstrated. In addition, there was no major difference in terms of clinical parameters, laboratory findings, and drug safety in patients between EMPA and DAPA.https://cdn.istanbul.edu.tr/file/JTA6CLJ8T5/A4D4179A8B4040629597C48450358B95type 2 diabetes mellitussodium-glucose cotransportersempagliflozindapagliflozin |
| spellingShingle | Ramazan Çakmak Golpouneh Alizad Oghyanous Özlem Soyluk Selçukbiricik Kubilay Karşıdağ EFFICACY OF SGLT-2 INHIBITORS IN THE TREATMENT OF TYPE 2 DIABETES: SINGLE CENTRE EXPERIENCE İstanbul Tıp Fakültesi Dergisi type 2 diabetes mellitus sodium-glucose cotransporters empagliflozin dapagliflozin |
| title | EFFICACY OF SGLT-2 INHIBITORS IN THE TREATMENT OF TYPE 2 DIABETES: SINGLE CENTRE EXPERIENCE |
| title_full | EFFICACY OF SGLT-2 INHIBITORS IN THE TREATMENT OF TYPE 2 DIABETES: SINGLE CENTRE EXPERIENCE |
| title_fullStr | EFFICACY OF SGLT-2 INHIBITORS IN THE TREATMENT OF TYPE 2 DIABETES: SINGLE CENTRE EXPERIENCE |
| title_full_unstemmed | EFFICACY OF SGLT-2 INHIBITORS IN THE TREATMENT OF TYPE 2 DIABETES: SINGLE CENTRE EXPERIENCE |
| title_short | EFFICACY OF SGLT-2 INHIBITORS IN THE TREATMENT OF TYPE 2 DIABETES: SINGLE CENTRE EXPERIENCE |
| title_sort | efficacy of sglt 2 inhibitors in the treatment of type 2 diabetes single centre experience |
| topic | type 2 diabetes mellitus sodium-glucose cotransporters empagliflozin dapagliflozin |
| url | https://cdn.istanbul.edu.tr/file/JTA6CLJ8T5/A4D4179A8B4040629597C48450358B95 |
| work_keys_str_mv | AT ramazancakmak efficacyofsglt2inhibitorsinthetreatmentoftype2diabetessinglecentreexperience AT golpounehalizadoghyanous efficacyofsglt2inhibitorsinthetreatmentoftype2diabetessinglecentreexperience AT ozlemsoylukselcukbiricik efficacyofsglt2inhibitorsinthetreatmentoftype2diabetessinglecentreexperience AT kubilaykarsıdag efficacyofsglt2inhibitorsinthetreatmentoftype2diabetessinglecentreexperience |